345 related articles for article (PubMed ID: 16414370)
1. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
3. Novel radiation sensitizers targeting tissue hypoxia.
Rowinsky EK
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
[TBL] [Abstract][Full Text] [Related]
4. [Radiation sensitizers: with special reference to hypoxic cell sensitizers].
Onoyama Y; Nakajima T; Tanaka M
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):894-903. PubMed ID: 3963856
[TBL] [Abstract][Full Text] [Related]
5. Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
Charpentier MM
Ann Pharmacother; 2005 Dec; 39(12):2038-45. PubMed ID: 16249270
[TBL] [Abstract][Full Text] [Related]
6. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
7. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
8. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
9. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez G; Giuliani A
J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
[TBL] [Abstract][Full Text] [Related]
10. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
11. Efaproxiral (Allos Therapeutics).
Kolman A
IDrugs; 2003 Aug; 6(8):795-801. PubMed ID: 12917776
[TBL] [Abstract][Full Text] [Related]
12. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
13. Modulating the radiation response.
Coleman CN
Stem Cells; 1996 Jan; 14(1):10-5. PubMed ID: 8820945
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
17. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
[TBL] [Abstract][Full Text] [Related]
18. Novel radiosensitizers for tumors of the central nervous system.
Mehta MP; Suh JH
Curr Opin Investig Drugs; 2004 Dec; 5(12):1284-91. PubMed ID: 15648950
[TBL] [Abstract][Full Text] [Related]
19. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
McKeown SR; Friery OP; McIntyre IA; Hejmadi MV; Patterson LH; Hirst DG
Br J Cancer Suppl; 1996 Jul; 27():S39-42. PubMed ID: 8763843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
